Wow, this guy is smart. I guess they don't give out PhD's to just anyone. Fall is the season for Bio-tech. According to Han Li, there are 17 medical coferences between September and December and countless companies revealing results for their latest drugs. He gave me the real story behind Erbitux's affect on Imclone (IMCL:NASDAQ) and describes the promising partnerships of Aspreva Pharmaceuticals (ASPV:NASDAQ). As if that wasn't enough, he told about Arqule Inc. (ARQL:NASDAQ). This is a $7.50 Bio-tech company which he believes can double over the next year.
You can't spell Bio-tech without io-tec. Listen In!
http://www.wallstreetreporter.com/page.php?page=featured&id=26804
Subscribe to:
Post Comments (Atom)
2 comments:
WadaUtere
[url=http://healthplusrx.com/vertigo]vertigo[/url]
Gasygenna
Great post on stanford.
Post a Comment